SOUTH SAN FRANCISCO, Calif., – January 2, 2019 – Taiwan Liposome
Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty
pharmaceutical company dedicated to the development and commercialization of
novel nanomedicines designed to target areas of unmet medical need in pain
management, ophthalmology and oncology, today announced that the Company will
attend and participate in investor meetings at the 37th Annual J.P.
Morgan Healthcare Conference being held from January 7-11 at the Westin St.
Francis in San Francisco, CA.|